Future studies may thus be needed to examine whether PD astrocytes carrying LRRK2 mutation have defects in mitochondrial or ER-related pathways like DAn, and test their contribution to inflammatory-dependent alterations. This evidence concerns the gene LRRK2 and Parkinson disease.